ArticleJournal of clinical microbiology2008
Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
Article in Journal of clinical microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Species-specific antifungal resistance trends in yeast bloodstream isolates causing candidemia before, during, and after the COVID-19 pandemic: insights from the INVIFAR Mexican multicenter network.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Antifungal Susceptibility and Resistance-Associated Gene Expression in NosocomialJournal of fungi (Basel, Switzerland) · 2025Article
- Antibiofilm sustainable strategies: pomegranate extract from agri-food waste as a natural antifungal against emergingFrontiers in microbiology · 2025Article
- The microbiology, epidemiology, risk factors, and clinical therapy of candidemia in burn patients hospitalized in Velayat Teaching Hospital, Rasht, northern Iran.Iranian journal of microbiology · 2024Article
- Prevalence and Species Distribution ofJournal of fungi (Basel, Switzerland) · 2024Article
- Article
- Meyerozyma guilliermondii species complex: review of current epidemiology, antifungal resistance, and mechanisms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Review
- Clinical, epidemiological, and mycological features of patients with candidemia: Experience in two tertiary referral centers in Iran.Current medical mycology · 2022Article
- Comparative Analysis of Epidemiological and Clinical Characteristics Between InvasiveInfection and drug resistance · 2022Article
- Virulence Factors as Promoters of Chronic Vulvovaginal Candidosis: A Review.Mycopathologia · 2021Review
- Active Flavonoids fromMolecules (Basel, Switzerland) · 2021Article
- Epidemiology, risk factors and outcomes ofEpidemiology and infection · 2019Article
- Article
- FTIR and Raman Spectroscopy-Based Biochemical Profiling Reflects Genomic Diversity of ClinicalInternational journal of molecular sciences · 2019Article
- Subgingival areas as potential reservoirs of different Candida spp in type 2 diabetes patients and healthy subjects.PloS one · 2019Observational
- Liposomal and Deoxycholate Amphotericin B Formulations: Effectiveness against Biofilm Infections of Candida spp.Pathogens (Basel, Switzerland) · 2017Article
- Revisiting Species Distribution and Antifungal Susceptibility of Candida Bloodstream Isolates from Latin American Medical Centers.Journal of fungi (Basel, Switzerland) · 2017Review
- Efficacy and safety of itraconazole use in infants.World journal of pediatrics : WJP · 2016Review
- Clinico-microbiological study of candidemia in a tertiary care hospital of southern part of India.Iranian journal of microbiology · 2015Article
- In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates.Journal of medical microbiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During a 3-year surveillance program (2004 to 2007) in Monterrey, Mexico, 398 isolates of Candida spp. were collected from five hospitals. We established the species distribution and in vitro susceptibilities of these isolates. The species included 127 Candida albicans strains, 151 C. parapsilosis strains, 59 C. tropicalis strains, 32 C. glabrata strains, 11 C. krusei strains, 5 C. guilliermondii strains, 4 C. famata strains, 2 C. utilis strains, 2 C. zeylanoides strains, 2 C. rugosa strains, 2 C. lusitaniae strains, and 1 C. boidinii strain. The species distribution differed with the age of the patients. The proportion of candidemias caused by C. parapsilosis was higher among infants <or=1 year old, and the proportion of candidemias caused by C. glabrata increased with patient age (>45 years old). MICs were calculated following the criteria of the Clinical Laboratory Standards Institute reference broth macrodilution method. Overall, C. albicans, C. parapsilosis, and C. tropicalis isolates were susceptible to fluconazole and amphotericin B. However, 31.3% of C. glabrata isolates were resistant to fluconazole (MIC >or= 64 microg/ml), 43.3% were resistant to itraconazole (MIC >or= 1 microg/ml), and 12.5% displayed resistance to amphotericin B (MIC >or= 2 microg/ml). Newer triazoles, namely, voriconazole, posaconazole, and ravuconazole, had a notable in vitro activity against all Candida species tested. Also, caspofungin was active against Candida sp. isolates (MIC(90) <or= 0.5 microg/ml) except C. parapsilosis (MIC(90) = 2 microg/ml). It is imperative to promote a national-level surveillance program to monitor this important microorganism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.